In fact, anti-PD-L1 therapy after chemo-radiation improved the PFS and OS in patients with NSCLC (PACIFIC trial)8,9, and induction treatment with irradiation followed by nivolumab provided clinical benefit in patients with metastatic triple-negative breast cancer (TONIC trial)13. The gene discussed is CD274; the disease is triple-negative breast carcinoma.